Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology | Psychiatry/Psychology
Disease Category: Attention Deficit/Hyperactivity Disorder (ADHD - Adults)
Trial Information
An Open-Label Pilot Study of Namenda (memantine hydrochloride) in Adult Subjects with Attention Deficit Hyperactivity Disorder (ADHD)
The main aim of this research study is to assess the effectiveness and tolerability of an investigational medication in Adults with Attention Deficit Hyperactivity Disorder (ADHD) and Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS). ADHD NOS is a label used to describe adults who have symptoms of ADHD that can appear in late childhood, or even adulthood. This study is a 12-week open-label (involves active medication only, no chance of placebo) trial of Namenda. Namenda is FDA approved for the treatment of Alzheimer’s disease, but is not approved for treatment of ADHD. Study participation could last for up to 14 weeks from the initial psychiatric evaluation. Participants will receive an evaluation and study visits at no cost.
PPPC Research
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114
Phone: 617-724-ADHD
EMail: pppcresearch@partners.org
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
